胸部CT上总气道计数与肺炎体积的整合评估作为冠状病毒病预后生物标志物
该多中心回顾性队列纳入781例住院COVID-19患者,用人工智能分割气道树和肺炎区域,测量总气道计数(TAC)和肺炎体积百分比。以肺炎体积百分比17.6%和TAC 255为界值分为四组,高TAC且高肺炎体积组(D组)校正后严重结局风险显著更高。3个月随访中重症患者肺炎体积改善而TAC未改善,提示TAC联合肺炎体积可预测严重结局。
要点
- 以肺炎体积百分比17.6%和TAC 255为界值将患者分为四组,D组(高TAC、高肺炎体积)结局最差。
- 严重结局患者TAC更高,D组校正年龄、BMI、性别、全肺体积和合并症后严重结局风险仍显著更高。
- 3个月随访中重症病例肺炎体积改善,但TAC未见改善。
核心结论
- TAC与肺炎体积的整合评估能有效预测COVID-19患者的严重结局。
研究设计与样本
- 多中心回顾性队列,纳入日本781例住院COVID-19患者,使用人工智能分割胸部CT气道树和肺炎区域,测量TAC和肺炎体积,参考标准为严重结局(高流量氧疗、有创机械通气或死亡)。
关键影像表现/征象
- 严重结局患者TAC更高。
- 以肺炎体积百分比17.6%和TAC 255为界值分为四组:A组(低TAC、低肺炎体积)、B组(高TAC、低肺炎体积)、C组(低TAC、高肺炎体积)、D组(高TAC、高肺炎体积)。
- D组结局最差,炎症、纤维化标志物和并发症水平最高。
诊断标准与关键数值
- 肺炎体积百分比界值为17.6%,TAC界值为255。
- 按上述界值分为四组,D组(高TAC且高肺炎体积)严重结局风险最高。
- 严重结局定义为高流量氧疗、有创机械通气或死亡。
临床应用与阅片要点
- 可关注胸部CT上TAC与肺炎体积的整合评估,用于COVID-19患者严重结局风险分层。
- 作者认为该指标可能适用于包括感染性或间质性肺炎在内的多种呼吸系统疾病。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The clinical relevance of computed tomography (CT)-based airway tree structure is unclear. Herein, we used artificial intelligence to segment the airway tree and pneumonia regions, measuring total airway count (TAC) and pneumonia volume to examine whether their combination is more closely associated with clinical outcomes in patients with coronavirus disease (COVID-19) than pneumonia volume alone.
MATERIALS AND METHODS: We examined clinical data and chest CT from 781 hospitalized COVID-19 patients in a multicenter retrospective cohort in Japan, focusing on the percentage of critical outcomes (high-flow oxygen, invasive mechanical ventilation, or death). Additionally, 197 patients were followed up for 3 months to monitor TAC and pneumonia volume.
RESULTS: Critical outcomes were observed in 63 (8.8%) patients, with higher TAC in those patients. Patients were divided into four groups based on cutoff values of 17.6% for pneumonia volume percent and 255 for TAC: Group A (low TAC, low pneumonia volume), Group B (high TAC, low pneumonia volume), Group C (low TAC, high pneumonia volume), and Group D (high TAC, high pneumonia volume). Group D had the worst outcomes, highest levels of inflammation, fibrosis markers, and complications, as well as a significantly higher risk of critical outcomes after adjusting for age, body mass index, sex, total lung volume and comorbidities. In the 3-month longitudinal analysis, pneumonia volume, but not TAC, improved in critical cases.
CONCLUSIONS: The integrated assessment of TAC and pneumonia volume effectively predicted critical outcomes in COVID-19 patients and may be useful for various respiratory diseases, including infectious or interstitial pneumonia.
KEY POINTS: Question Total airway counts (TAC) on computed tomography (CT) scan is associated with respiratory disease progression, but clinical relevance of CT-based airway tree structure is unclear. Findings The integrated assessment of TAC and pneumonia volume effectively predicted critical outcomes in COVID-19 patients. Clinical relevance This metric can potentially be applied to various respiratory diseases, including infectious or interstitial pneumonia.
引用
- Nakagawara K, Tanabe N, Chubachi S, et al. Integrated assessment of total airway count and pneumonia volume on chest computed tomography as a prognostic biomarker for coronavirus disease. Eur Radiol. 2025. PMID: 41442001. doi:10.1007/s00330-025-12078-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。